Skip to main content

Immune training enhances anti-viral responses and improves outcomes in Pax5 mice susceptible to chronic infection.

EMBO molecular medicine

Authors: Zhe Lu, Olivia Stencel, Wei Liu, Eleni Vasileiou, Haifeng C Xu, Piyush Pandey, Paweł Stachura, Abdelrahman Elwy, Anastassia Tsombal, Ann-Sophie Mai, Franziska Auer, Mina N F Morcos, Maximilian Seidl, Sarah Koziel, Peter-Martin Bruch, Sascha Dietrich, Sarah Elitzur, Gunther Hartmann, Karl S Lang, Stefan Janssen, Ute Fischer, Sanil Bhatia, Philipp A Lang, Arndt Borkhardt, Julia Hauer, Aleksandra A Pandyra

Viral infections pose a significant global burden. Host susceptibility to pathogens is determined by many factors including genetic variation that can lead to immunodeficient or dysregulated antiviral immune responses. Pax5 heterozygosity (Pax5), resulting in reduced PAX5 levels in mice, mimics germline or somatic PAX5 dysregulation contributing to diseases such as childhood B-cell precursor acute lymphoblastic leukemia (B-ALL). In contrast to the well-characterized roles of PAX5 during early B-cell development, little is known about how Pax5 heterozygosity impacts antiviral responses. We infected Pax5 mice with the noncytopathic Lymphocytic Choriomeningitis Virus (LCMV) and found that infection with the chronic Docile strain resulted in decreased survival of Pax5 mice. While early adaptive CD8 T-cell (CTL) immunity was robust in Pax5 mice, LCMV-specific neutralizing antibody production was compromised leading to impaired long-term viral clearance and a pro-inflammatory milieu in the bone marrow (BM). Here we show that survival outcomes were improved upon prophylactic treatment with the β-glucan immune trainer through induction of heterologous protection against chronic infection. β-Glucan enhanced viral clearance, CTL immunity, neutralizing antibody production and reduced monocyte immunosuppression in multiple LCMV-resident host organs. New insight from this study will help design effective prophylactic treatment strategies against chronic viral infections, particularly in genetically predisposed susceptible hosts.

© 2025. The Author(s).

PMID: 40082582

Participating cluster members